Table 1. Small molecules; targeted therapies of atopic dermatitis.

Category	Target	Name	Formulation	Development status
JAK inhibitors	JAK1	Upadacitinib	Oral	Ph III on-going
		Abrocitinib	Oral	Ph III completed
	JAK1/2	Baricitinib	Oral	Ph III completed
		Ruxolitinib	Topical	Ph III on-going, completed
	JAK1/3	Tofacitinib	Oral/topical	Ph II completed (topical)
	Pan JAK	ASN002	Oral	Ph II completed
		Delgocitinib	Topical	Ph II on-going
PDE4 inhibitors	PDE4	Apremilast	Oral	Ph II completed
		Roflumilast	Topical	Ph II completed
		Crisaborole	Topical	Approved
		Opa-15406	Topical	Ph III on-going
		DRM-02	Topical	Ph II completed
		LEO29102	Topical	Ph II completed

JAK: Janus kinase, PDE4: phosphodiesterase enzyme 4.